OASIS

Why it matters

The OASIS project is focused on addressing the challenge of resistance to antibody drug conjugates (ADCs), which have shown significant promise in treating various cancers but often encounter resistance over time. To better understand and overcome this resistance, OASIS will create a biobank of patient-derived organoids (PDOs) that more accurately model how ADC resistance develops. The project will integrate advanced techniques, including whole-body molecular imaging, circulating tumor cell analysis, plasma proteomics, multiplex immunofluorescence, and AI-enhanced digital pathology, to identify and study the multiple mechanisms of resistance. By developing these tools, OASIS aims to discover biomarkers that can guide future treatment decisions for patients who progress on ADC therapies, ultimately improving clinical outcomes.

CPE’s role in the project

Our role in project is to provide the patients perspective to the project by creating a patient advisory board that will not only provide feedback on project but also review the results so that they can be disseminated in patient friendly manner.

Partners

1. INSTITUT GUSTAVE ROUSSY, France
2. INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE
MEDICALE, France
3. UNICANCER, France
4. COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES
ALTERNATIVES, France
5. OLINK PROTEOMICS, Sweden
6. ELIKYA THERAPEUTICS SAS, France
7. ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON, Greece
8. ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE JULES BORDET, Belgium
9. ORAKL ONCOLOGY SAS, France
10. CENTRALESUPELEC, France
11. CANCER PATIENTS EUROPE, Belgium
12. PANEPISTIMIO KRITIS, Greece